Concordia International Corp.’s Latest 50% Drop Is Attracting Some Institutional Investors

Concordia International Corp. (TSX:CXR)(NASDAQ:CXRX) is caught in the wake of dismal earnings reports, negative sentiment about the pharmaceutical industry’s pricing practices, and actions of its management team.

The Motley Fool

Concordia International Corp.’s (TSX:CXR)(NASDAQ:CXRX) stock has been under some fierce pressure lately after a slew of negative news, dismal quarterly results, and industry pressures that have dragged the stock to a recent 52-week low. This is a company that was valued at $2 billion less than four months ago.

Since the last half of 2015 the pharmaceutical industry has faced pressure from government and private agencies cracking down on its pricing practices. This hasn’t gone over well with the public, and considering the outcome of the U.S. elections, this negative sentiment is likely to continue into the near term.

The company was also affected by a dismal Q2 2016 earnings release, which was underpinned by a $567 million impairment charge. In addition, it reported $2.4 million in foreign exchanges loses due to the Brexit. This translated into a loss of $11.28 per share.

All of this has weighed heavily on the company’s stock, dragging it down by approximately 80% from its 2016 high of $57.70 per share.

A turnaround story

There still remains some uncertainty about the direction of the industry; however, most companies have realized this and are taking the necessary steps to reduce their cost structure to offset the expectation of lower prices. Hence, Concordia’s $567 million write-down with respect to two North America segment products: Nilandron and Plaquenil.

The company attributed these impairment charges to competitive market pressures and decreased sales volumes. During the quarter the company recorded $306,189 impairment with respect to Nilandron and $260,887 impairment with respect to Plaquenil.

If you’re concerned about the company’s solvency, the impairment charge and foreign exchange loss did reduce the company’s shareholder’s equity by $789, increasing its debt-to-equity ratio to 9.5 times, which is a little unnerving. However, the company has stated it’s confident that it will be able to service any debt obligations.

If you set aside the impairment charge and examine its Q2 financial results year over year, they paint a slightly brighter picture. Revenues increased by $351 million, or 321%, of which 60% of those revenues were from the Concordia’s international business segments. This is beneficial considering the low Canadian dollar. Using the sales-comparison method, selling, marketing, G&A, and R&D costs decreased by approximately 7% year over year, indicating that the company is adapting to an expectation of a lower price environment.

A signal that the company’s stock could be oversold is the growing interest from private equity firms. This week famed billionaire investor Steve Cohen’s firm, Point72 Asset Management, filed a Form 13G with the SEC reporting that it had acquired 5.8% of the company’s outstanding shares.

It may be a long shot, but a possible acquisition shouldn’t be ruled out once there is some more pricing certainty in the industry. Earlier in the year, the company was the target of a potential takeover by the Blackstone Group LP, which priced the company at $2 billion, or $38.65 a share.

Value investors should place this stock on their speculative buy list and monitor its trading activity. It may remain out of favour in the near term, but once the dust settles, there could be significant upside potential.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Scott Brandt has no position in any stocks mentioned.

More on Dividend Stocks

A person builds a rock tower on a beach.
Dividend Stocks

CPP Pension: Boost Your Payouts by $5,232 per Year

You can raise your after-tax CPP by making RRSP contributions. Alimentation Couche-Tard (TSX:ATD) is a good RRSP stock.

Read more »

A close up image of Canadian $20 Dollar bills
Dividend Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

Here are three no-brainer stocks that are suitable for anyone getting started on their investing journey.

Read more »

growing plant shoots on stacked coins
Dividend Stocks

3 Top Dividend Stocks That Keep Raising Their Payouts

These three TSX stocks are ideal buy as they consistently raise their payouts, depicting their healthy financials.

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

This 5% Dividend Stock Pays Cash Every Month

This monthly dividend stock offers cash every month, but also returns that continue to climb higher from being in a…

Read more »

Solar panels and windmills
Dividend Stocks

How Much Will TransAlta Renewables Pay in Dividends This Year?

TransAlta Corporation’s (TSX:TA) acquisition of TransAlta Renewables stock holds significant implications for income-oriented investors who previously held this monthly dividend…

Read more »

Dividend Stocks

3 Stocks That Can Help You to Get Richer in the Next 5 Years

Consistent growth stocks with a relatively bright future are one of the most trustworthy ways to grow wealth.

Read more »

Dividend Stocks

3 Blue-Chip Stocks Every Canadian Should Own

These Canadian blue-chip stocks are backed by well-established businesses and a growing earnings base, enabling them to generate above-average returns.

Read more »

grow money, wealth build
Dividend Stocks

Is This 7.25%-Yielding Dividend Grower the Ultimate Income Stock?

This top Canadian dividend stock has increased the distribution annually for nearly three decades.

Read more »